Advertisement

Cyclosporine

  • Robert A. Maxwell
  • Shohreh B. Eckhardt

Abstract

Prior to the discovery of cyclosporine, azathioprine was the mainstay of immunosuppressant therapy. According to White (1982a), the discovery of azathioprine in 1959 and its subsequent combination with steroids established kidney transplantation as a viable therapy for renal failure. However, although this regimen represented a major step forward, only 50% of the allografts (homografts) achieved with it were functional, and these were accompanied by a 15% mortality rate from secondary infection. Half of the transplanted kidneys were lost within 12 months as a result of rejection (Kahan, 1983; White, 1982b). In only two situations was azathioprine plus corticosteroids consistently effective in renal transplantation: (1) where donors were living, reasonably immune-compatible relatives, or (2) where cadaver organs were given to recipients who tested as weak immune responders. Unfortunately, in the USA, the majority of the young, vigorous population requiring transplants test as strong immune responders (Kahan, 1981).

Keywords

Drug Discovery Cadaveric Renal Transplantation Heart Allograft Immune Responder Tolypocladium Inflatum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berkow, R., ed.: Immunology; allergic-disorders, in The Merck Manual, 14th Ed., pp. 265–347, Merck Sharp & Dohme Research Laboratories, Rahway, NJ, 1982.Google Scholar
  2. Borel, J. F.: Cyclosporin-A, Present experimental status. Transplant. Proc. 13: 344–348, 1981.PubMedGoogle Scholar
  3. Borel, J. F.: The history of cyclosporin A and its significance, in Cyclosporin A, D. J. G. White, ed., pp. 5–17, Elsevier, Amsterdam, 1982.Google Scholar
  4. Borel, J. F.: Cyclosporine: Historical perspectives. Transplant. Proc. 15 (Suppl. 1): 2219–2229, 1983.Google Scholar
  5. Borel, J. F., Feurer, C., Gubler, H. U., and Stähelin, H.: Biological effects of cyclosporin A: A new anti-lymphocytic agent. Agents Actions 6:468–475, 1976.PubMedCrossRefGoogle Scholar
  6. Borel, J. F., Feurer, C., Magneé, G, and Stähelin, H.: Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32:1017–1025, 1977.PubMedGoogle Scholar
  7. Came, R. Y. and White, D. J. G.: Cyclosporin A—A powerful immunosup-pressant in dogs with renal allografts. IRCS Med. Sci. 5:595, 1977.Google Scholar
  8. Calne, R. Y., White, D. J. G., Rolles, K., Smith, D. P., and Herbertson, B. M.: Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet 1:1183–1185, 1978a.PubMedCrossRefGoogle Scholar
  9. Calne, R. Y., White, D. J. G., Thiru, S., Evans, D. B., McMaster, P., Dunn, D. C., Craddock, G. N., Pentlow, B. D., and Rolles, K.: Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2:1323–1327, 1978b.PubMedCrossRefGoogle Scholar
  10. Calne, R. Y., Rolles, K., White, D. J. G., Thiru, S., Evans, D. B., McMaster, P., Dunn, D. C., Craddock, G. N., Henderson, R. G., Aziz, S., and Lewis, P.: Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32kidneys, 2 pancreases and 2 livers. Lancet2:1033–1036, 1979.Google Scholar
  11. The Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation: Analysis at three years. N. Engl. J. Med. 314:1219–1225, 1986.CrossRefGoogle Scholar
  12. Cohen, D. J., Loertscher, R., Rubin, M. F., Tilney, N. L., Carpenter, C B., and Strom, T. B.: Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann. Intern. Med. 101:667–682, 1984.PubMedGoogle Scholar
  13. Cooley, D. A., Frazier, O. H., Painvin, G. A., Boldt, L., and Kahan, B. D.: Cardiac and cardiopulmonary transplantation using cyclosporine for immunosuppression: Recent Texas Heart Institute experience. Transplant Proc. 15 (Suppl. 1): 2567–2572, 1983.Google Scholar
  14. Dreyfuss, M., Harri, E., Hofmann, H., Kobel, H., Pache, W., and Tscherter, H.: Cyclosporin A and C. New metabolites from Trichodermapolysporum (link ex pers) rifai. Eur. J. Applied Microbiol. 3:125–133, 1976.Google Scholar
  15. Herold, K. C. and Rubenstein, A. H.: Immunosuppression for insulin-dependent diabetes. N. Engl. J. Med. 318:701,702,1989.CrossRefGoogle Scholar
  16. Hess, A. D., Colombani, P. M. and Esa, A.: Cyclosporine: Immunologie aspects in transplantation, in Kidney Transplant Rejection: Diagnosis and Treatment, G. M. Williams, J. F. Burdick, and K. Solez, eds., pp. 353–382, Marcel Dekker, New York, 1986.Google Scholar
  17. Kahan, B. D.: Cosmas and Damian in the 20th century? N. Engl. J. Med. 305: 280,281,1981.PubMedCrossRefGoogle Scholar
  18. Kahan, B.D.: Cosmas and Damian revisited. Transplant. Proc. 15 (Suppl. 1): 2211–2216, 1983.PubMedGoogle Scholar
  19. Kahan, B. D.: Cyclosporine: The agent and its actions. Transplant. Proc. 17 (Suppl. 1): 5–18, 1985.PubMedGoogle Scholar
  20. Kahan, B.D., ed.: Symposium. First international congress on cyclosporine. Transplant. Proc. 15 (Suppls. 1,2): 2207–3188, 1983.Google Scholar
  21. Kostakis, A. J., White, D. J. B., and Calne, R. Y.: Prolongation of rat heart allograft survival by cyclosporin A. IRCS Med. Sci. 5:280, 1977.Google Scholar
  22. Kupiec-Weglinski, J. W., Filho, M. A., Strom, T. B.,and Tilney, N. L.: Sparing of suppressor cells: A critical action of cyclosporine. Transplantation 38: 97–101, 1984.PubMedCrossRefGoogle Scholar
  23. Lampe, K. F., ed.: Immunomodulators, in Drug Evaluations, 6th Ed., pp. 1147–1165, American Medical Association, Chicago, 1986.Google Scholar
  24. Morris, P. J.: Cyclosporin A. Transplantation 32:349–354, 1981.PubMedCrossRefGoogle Scholar
  25. Morris, P. J.: Cyclosporine, in Kidney Transplantation: Principles and Practice, P. J. Morris, ed., pp. 261–279, Grune and Stratton, London, 1984.Google Scholar
  26. Petcher, T. J., Weber, H. P., and Rüegger, A.: Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv. Chim. Ada 59:1480–1488, 1976.CrossRefGoogle Scholar
  27. Powles, R. L., Barrett, A. J., Clink, H., Kay, H. E. M., Sloane, J., and McElwain, T. J.: Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet 2:1327–1331, 1978.PubMedCrossRefGoogle Scholar
  28. Powles, R. L., Clink, H. M., Spence, D., Morgenstern, G., Watson, J. G., Selby, P. J., Woods, M., Barrett, A., Jameson, B., Sloane, J., Lawler, S. D., Kay, H. E. M., Lawson, D., McElwain, T. J., and Alexander, P.: Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1:327–329, 1980.PubMedCrossRefGoogle Scholar
  29. Rüegger, A., Kuhn, M., Lichti, H., Loosli, H. R., Huguenin, R., Quiquerez, C., and von Wartburg, A.: Cyclosporin A, a peptide metabolite from Trichoierma polysporum Rifai with a remarkable immunosuppressive activity. Helv. Chim. Acta 59:1075–1092, 1976.PubMedCrossRefGoogle Scholar
  30. Sande, M. A. and Mandell, G. L.: Antimicrobial agents. General considerations, in The Pharmacological Basis ofTherapeutics, 7th Ed., A. G. Gilman, L. S. Goodman, T. W. Rail, and F. Murad, eds., pp. 1066–1094, Macmillan, New York, 1985.Google Scholar
  31. Starzl, T.E.: Clinical aspects of cyclosporine therapy: A summation. Transplant Proc. 15 (Suppl. 1): 3103–3107, 1983.PubMedGoogle Scholar
  32. Starzl, T. E., Hakala, T. R., Rosenthal, J. T., Iwatsuki, S., and Shaw, B. W., Jr.: The Colorado-Pittsburgh cadaveric renal transplantation study with cyclosporine. Transplant. Proc. 15 (Suppl. 1): 2459–2462, 1983.Google Scholar
  33. Starzl, T. E., Iwatsuki, S., Klintmalm, S., Schröter, G. P. J., Weil, R. III, Koep, L. J., and Porter, K. A.: Liver transplantation, 1980, with particular reference to cyclosporin-A. Transplant. Proc. 13 (No. 1): 281–285, 1981.PubMedGoogle Scholar
  34. Starzl, T. E., Weil, R. III, Iwatsuki, S., Klintmalm, G., Schröter, G. P. J., Koep, L. J., Iwaki, Y., Terasaki, P. I., and Porter, K. A.: The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg. Gynecol. Obstet. 151:17–26, 1980.PubMedGoogle Scholar
  35. Storb, R., Deeg, H. J., Whitehead, J., Farewell, V., Appelbaum, F. R., Beatty, P., Bensinger, W., Buckner, C. D., Clift, R. A., Doney, K., Hansen, J. A., Hill, R., Lum, L. G., Martin, P., McGuffin, R., Sanders, J. E., Singer, J., Stewart, P., Sullivan, K. M., Witherspoon, R. P., and Thomas, E. D.: Marrow transplantation for leukemia and aplastic anemia: Two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Transplant. Proc. 19:2608–2613, 1987.PubMedGoogle Scholar
  36. Sutherland, D. E. R., Goetz, F. C., and Najarian, J. S.: Pancreas transplants from related donors. Transplantation 38:625–633, 1984.PubMedCrossRefGoogle Scholar
  37. Tutschka, P. J.: Cyclosporin A—A new outlook for immunosuppression in clinical transplantation. Blut 39:81–87, 1979.PubMedCrossRefGoogle Scholar
  38. Wenger, R.: Synthesis of cyclosporine and analogues. Structure activity relationships of new cyclosporine derivatives. Transplant. Proc. 15 (Suppl. 1): 2230–2241, 1983.Google Scholar
  39. White, D. J. G.: Foreword to Cyclosporin A, D. J. G. White, ed., p. v, Elsevier Biomédical, Amsterdam, 1982a.Google Scholar
  40. White, D.J.G.: Cyclosporin A. Clinical pharmacology and therapeutic potential. Drugs 24:322–334, 1982b.PubMedCrossRefGoogle Scholar
  41. White, D.J.G., Plumb, A. M., Pawelec, G., and Brons, G.: Cyclosporin A: An immunosuppressive agent preferentially active against proliferating T cells. Transplantation 27:55–58, 1979.PubMedCrossRefGoogle Scholar
  42. Williams, G. M., Burdick, J. F., and Solez, K.: Preface, in Kidney Transplant Rejection: Diagnosis and Treatment, G. M. Williams, J. F. Burdick, and K. Solez, eds., pp. v,vi, Marcel Dekker, New York, 1986.Google Scholar
  43. Wood, R. F. M., Thompson, J. F., Allen, N. H., Ting, A., and Morris, P. J.: The consequences of conversion from cyclosporine to azathioprine and pred-nisolonein renal allograft recipients. Transplant. Proc. 15(Suppl. 1): 2862–2868, 1983.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Robert A. Maxwell
    • 1
  • Shohreh B. Eckhardt
    • 2
  1. 1.The Wellcome Research Laboratories ResearchTriangle ParkUSA
  2. 2.University of Vermont College of MedicineBurlingtonUSA

Personalised recommendations